Methods of using diacerein as an adjunctive therapy for diabetes

一种双醋瑞因、糖尿病的技术，应用在用于II型糖尿病的治疗,治疗II型糖尿病患者的治疗领域，能够解决患者不能达到治疗目标等问题

Inactive Publication Date: 2013-01-02
TWI BIOTECH
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Despite the presence of antidiabetic drugs, some patients do not achieve treatment goals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of using diacerein as an adjunctive therapy for diabetes
  • Methods of using diacerein as an adjunctive therapy for diabetes
  • Methods of using diacerein as an adjunctive therapy for diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Randomized, double-blind, placebo-controlled study of diacerein in patients with uncontrolled type 2 diabetes mellitus Research

[0048] Objective: To evaluate the efficacy and safety of diacerein in the treatment of type 2 diabetes mellitus (DM).

[0049] Primary endpoint: Add-on diacerein versus no add-on treatment (placebo) on glycosylated hemoglobin (HbA1c) after 24 weeks of double-blind treatment in patients with type 2 diabetes inadequately controlled by prior antidiabetic therapy ) effect.

[0050] Subjects: Male or female patients with type 2 diabetes (BMI ≤ 35 kg / m) on stable hypoglycemic monotherapy for at least 3 months prior to the screening visit 2 ). Hemoglobin A1c (HbA1c) measurements taken at the screening visit were between 7% and 12%. Patients enrolled in the study received one or more antihyperglycemic agents, including sulfonylureas, biguanides, alpha-glucosidase inhibitors, thiazolidinediones (TZDs), dipeptidyl peptidase-4 inhibitors (DPP-4 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods of treating type II diabetes using combinations of diacerein or its derivatives with other antidiabetic agents. The methods may also allow improving glycemic control of type II diabetes patients and / or reducing side effects and / or cardiovascular risks of antidiabetic agents.

Description

Background technique [0001] Diacerein, [4,5-bis(acetoxy)-9,10-dioxo-2-anthracenecarboxylic acid]) is a highly purified anthraquinone derivative. It has been approved as a symptom-modifying drug for osteoarthritis (SYSADOA) in several countries. Rhein is the main active metabolite of diacerein. Rhein has been shown to control blood glucose concentrations in rodent models of type 2 (or type II) diabetes. However, no studies have shown that diacerein controls blood sugar in humans with type 2 diabetes. There are no reports in the literature that diacerein can be used as an adjunct therapy for the treatment of type II diabetic patients with insufficient drug response to existing antidiabetic drug therapy. [0002] The prevalence of diabetes has increased worldwide. About seven percent of people aged 45-64 have diabetes and this number increases significantly among people over 65. There are two types of diabetes. In the type of diabetes known as type II, non-insulin-dependent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A01N35/00A61K31/12
CPCA61K38/28A61K31/427A61K31/145A61K31/277A61K31/225A61K31/155A61K45/06A61K31/426A61P13/12A61P29/00A61P43/00A61P5/50A61P9/00A61P9/04A61P9/10A61P3/10A61K2300/00A61K31/715A61K31/12
Inventor 文清·谢里·顾高丹晨卢威书陈千明林伊银
Owner TWI BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap